NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: LANXESS
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Rely+On Virkon from LANXESS Effective Against Monkeypox Virus - The high level disinfectant Rely+On Virkon from specialty chemicals company LANXESS is effective against the monkeypox virus - RelyOnDisinfection.com
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus

 

NewswireToday - /newswire/ - Cologne, North Rhine-Westphalia, Germany, 2022/09/07 - The high level disinfectant Rely+On Virkon from specialty chemicals company LANXESS is effective against the monkeypox virus - RelyOnDisinfection.com. FRA: DE Frankfurt: LXS

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Effectiveness of Rely+On Virkon scientifically proven;
• Disinfection a key to help prevent transmission;
• Hygiene best practices essential.

With cases of monkeypox continuing to rise and spread around the world, government health departments are providing advice and guidance on how to help prevent transmission of the disease with hygiene and disinfection of the utmost importance.

The high level disinfectant Rely+On Virkon from specialty chemicals company LANXESS is effective against the monkeypox virus. The product is used for hard surface disinfection in hospital, healthcare and institutional facilities, airports, public transport terminals, clinics, shopping malls and many other routes of transition. Francois Martignoni, Head of the Human Health Disinfectants Business at LANXESS: “Practicing good hygiene must always be a part of our everyday routines, but the selection of a disinfectant proven to kill the target pathogen is critical”.
Rely+On Virkon inactivates monkeypox virus quickly

Independent tests have proven that Rely+On Virkon inactivates a closely related surrogate of the currently spreading pox virus strain. “From these tests it can be concluded that Rely+On Virkon is also effective against monkeypox virus,” Martignoni said.

Rely+On Virkon achieved inactivation of the pox virus strain at a 1:100 dilution rate with a 15-minute contact time. This corresponds to test conditions set out by the French AFNOR Association and proves the performance and suitability of Rely+On Virkon for practical use.

Rely+On Virkon (relyondisinfection.com) is diluted for application and sprayed on hard surfaces. It can therefore help to reduce the risk of cross-contamination.

LANXESS’ Material Protection Products business unit produces a wide range of scientifically based biocide technologies under the Virkon brand.

About LANXESS

LANXESS (lanxess.com) is a leading specialty chemicals company with sales of EUR 6.8 billion in 2019. The company currently has about 14,400 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Forward-Looking Statements
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: LANXESS

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Rely+On Virkon from LANXESS Effective Against Monkeypox Virus

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Ilona Kawan - LANXESS.com 
+49 221 8885 1684 ilona.kawan[.]lanxess.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any LANXESS securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From LANXESS / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Collaboration Between Drug and Medical Food Manufacturers to Boost Market Growth Says Frost & Sullivan
Parexel Recognized by Frost & Sullivan with 2022 Global Customer Value Leadership Award
Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)